Novo Nordisk A/S: Diabetes Mellitus, Type 2 trials

The registry lists 633 Diabetes Mellitus, Type 2 studies with Novo Nordisk A/S as lead sponsor. 22 are open to participants now and 175 have results posted.

Phase 1 122Phase 2 37Phase 3 184Phase 4 75No phase 215(a study in two phases counts in both)

Studies

Page 5 of 7. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male SubjectsCompletedNCT01572753Phase 1
• Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 DiabetesCompletedNCT01565733
• Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 DiabetesCompletedNCT01562561Phase 3
• Efficacy and Safety of Levemir® Used as Basal InsulinCompletedNCT01548248
• Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 TreatmentCompletedNCT01548235
• Observational Study to Evaluate the Safety of Levemir® in Patients With DiabetesCompletedNCT01545791
• Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and HyposCompletedNCT01542489
• The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment SatisfactionCompletedNCT01542476
• Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 DiabetesCompletedNCT01542463
• An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes MellitusCompletedNCT01542424
• Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes MellitusCompletedNCT01542060
• Special Survey for Patients With Type 1 or Type 2 DiabetesCompletedNCT01538589
• Paediatric Subjects - Special SurveyCompletedNCT01538576
• Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy VolunteersCompletedNCT01538511Phase 1
• Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 DiabetesCompletedNCT01536652
• Physiological Concept of Insulin Therapy in Subjects With Type 2 DiabetesCompletedNCT01536639
• Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the NetherlandsCompletedNCT01536626
• Post Marketing Surveillance Study of Biphasic Insulin Aspart 30CompletedNCT01536613
• Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 DiabetesCompletedNCT01536600
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese SubjectsCompletedNCT01527630Phase 1
• Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 DiabetesCompletedNCT01527539Phase 3
• Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 DiabetesCompletedNCT01526980Phase 2
• Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With DiabetesCompletedNCT01520818Phase 3
• Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 DiabetesCompletedNCT01520753Phase 3
• Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 DiabetesCompletedNCT01517555Phase 1
• Effect of Liraglutide on Heart Frequency in Healthy VolunteersCompletedNCT01516255Phase 1
• Evaluation of Safety and Parameters of Application TechniqueCompletedNCT01516242
• Safety and Tolerability of Liraglutide in Healthy Japanese Male VolunteersCompletedNCT01515592Phase 1
• Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 DiabetesCompletedNCT01511692Phase 1
• Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic AgentCompletedNCT01511198Phase 2
• Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control GroupCompletedNCT01511185Phase 1
• Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 DiabetesCompletedNCT01511172Phase 2
• Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 DiabetesCompletedNCT01509755Phase 2
• Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 DiabetesCompletedNCT01509742Phase 1
• Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 DiabetesCompletedNCT01508949Phase 2
• Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT01508923Phase 2
• Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal WomenCompletedNCT01508858Phase 1
• Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney FunctionCompletedNCT01508806Phase 1
• Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver FunctionCompletedNCT01507389Phase 1
• Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 DiabetesCompletedNCT01507311Phase 1
• Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 DiabetesCompletedNCT01507285Phase 1
• Diabetes Attitudes Wishes and NeedsCompletedNCT01507116
• Observational Study of NovoNorm® in Subjects With DiabetesCompletedNCT01498913
• An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical PracticeCompletedNCT01498900
• Pharmacokinetics of Insulin Detemir in Subjects With Type 2 DiabetesCompletedNCT01497600Phase 1
• Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 DiabetesCompletedNCT01497561Phase 1
• Observational Study With InnoLet® in Daily Clinical PracticeCompletedNCT01492959
• Observational Study With Mixtard® 30 NovoLet® to Assess Patient SatisfactionCompletedNCT01492218
• NovoLet® Acceptance Study Within the Hospital Practise in IndonesiaCompletedNCT01492205
• Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical PracticeCompletedNCT01492166
• NovoLet® Surveillance Study on Using Human Insulin System in IndonesiaCompletedNCT01492153
• Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy VolunteersCompletedNCT01490658Phase 1
• Surveillance Study of NovoRapid® for New Drug Re-examinationCompletedNCT01490112
• Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy VolunteersCompletedNCT01489644Phase 1
• Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01487798Phase 4
• An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at BedtimeCompletedNCT01487421
• Special Survey for Type 1 or Type 2 Diabetic PatientsCompletedNCT01487408
• Special Survey for Paediatric SubjectsCompletedNCT01487382
• Special Survey of Production of Insulin Aspart Specific AntibodyCompletedNCT01487369
• Observational Study of Safety of NovoMix® 30 Treatment for Type 2 DiabetesCompletedNCT01486875
• Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADsCompletedNCT01486862Phase 4
• Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2CompletedNCT01484262
• A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 DiabetesTerminatedNCT01467414Phase 1
• Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 DiabetesCompletedNCT01467401Phase 4
• Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01467375Phase 3
• Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 DiabetesCompletedNCT01467323Phase 3
• Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 DiabetesCompletedNCT01465152Phase 4
• Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical PracticeCompletedNCT01454024
• Changing Diabetes® World TourCompletedNCT01437072
• Trial Investigating the Safety of NNC 0113-0987 in Healthy Male SubjectsCompletedNCT01405261Phase 1
• Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01403025
• Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in KoreaCompletedNCT01355718
• A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in IndiaCompletedNCT01351922
• Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01345734
• Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 DiabetesCompletedNCT01324505Phase 1
• Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01288326
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male SubjectsCompletedNCT01272973Phase 1
• Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01226966
• A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in IndiaCompletedNCT01212133
• A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 DiabetesCompletedNCT01154881Phase 1
• A Trial Investigating the Effect of NN5401 in Subjects With Type 2 DiabetesCompletedNCT01134224Phase 1
• A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 DiabetesCompletedNCT01121276Phase 1
• A Two Part Trial Investigating the Safety of NN9925 in Healthy Male SubjectsCompletedNCT01087645Phase 1
• An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese PatientsCompletedNCT01077570
• Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes TreatmentCompletedNCT01076842Phase 4
• The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic OriginCompletedNCT01043510Phase 1
• A Two Part Trial Investigating the Safety of NN9924 in Healthy Male SubjectsCompletedNCT01037582Phase 1
• A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 DiabetesCompletedNCT01028404Phase 1
• A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 DiabeticsCompletedNCT00993304Phase 1
• Safety of Liraglutide in Pediatric Patients With Type 2 DiabetesCompletedNCT00943501Phase 1
• A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in KoreaCompletedNCT00918151
• A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese SubjectsCompletedNCT00897169Phase 1
• A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in TaiwanCompletedNCT00887874
• A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in MalaysiaCompletedNCT00877526
• A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in PhilippinesCompletedNCT00874159
• Examination of the Effects of Liraglutide on the Mode of Action of Insulin DetemirCompletedNCT00873223Phase 1
• Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long NeedlesCompletedNCT00871416Phase 3
• Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic MedicationCompletedNCT00869908
• Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin TreatmentCompletedNCT00865397
• Observational Study on Levemir® in Obese Diabetic PatientsCompletedNCT00849342